| Literature DB >> 30762963 |
Berenice M Lang1, Panagiotis Balermpas2, Andrea Bauer3, Andreas Blum4, G Felix Brölsch5, Thomas Dirschka6,7, Markus Follmann8, Jorge Frank9, Bernhard Frerich10, Klaus Fritz11, Axel Hauschild12, Ludwig M Heindl13, Hans-Peter Howaldt14, Stephan Ihrler15, Vinodh Kakkassery16,17, Bernhard Klumpp18,19, Albrecht Krause-Bergmann20, Christoph Löser21, Markus Meissner22, Michael M Sachse23, Max Schlaak24, Michael P Schön9, Lutz Tischendorf25, Michael Tronnier26, Dirk Vordermark27, Julia Welzel28, Michael Weichenthal12, Susanne Wiegand29, Roland Kaufmann22, Stephan Grabbe1.
Abstract
Basal cell carcinoma (BCC) is the most common malignant tumor among fair-skinned individuals, and its incidence had been steadily rising in the past decades. In order to maintain the highest quality of patient care possible, the German S2k guidelines were updated following a systematic literature search and with the participation of all professional societies and associations involved in the management of the disease. Part 2 addresses issues such as proper risk stratification, the various therapeutic approaches, and prevention as well as follow-up of patients with basal cell carcinoma.Entities:
Mesh：
Year: 2019 PMID： 30762963 DOI： 10.1111/ddg.13755
Source DB: PubMed Journal: J Dtsch Dermatol Ges ISSN： 1610-0379 Impact factor: 5.584